SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-22-085140
Filing Date
2022-03-25
Accepted
2022-03-25 16:07:07
Documents
2
Group Members
CHRIS HOLLOWOODMARTIN MURPHYSYNCONA HOLDINGS LTDSYNCONA INVESTMENT MANAGEMENT LTDSYNCONA LTD

Document Format Files

Seq Description Document Type Size
1 SC 13D d263922dsc13d.htm SC 13D 127147
2 EX-99.1 d263922dex991.htm EX-99.1 6571
  Complete submission text file 0001193125-22-085140.txt   135659
Mailing Address 2ND FLOOR 8 BLOOMSBURY STREET LONDON X0 WC1B 3SR
Business Address 3RD FLOOR, ARNOLD HOUSE PO BOX 273, ST JULIAN'S AVENUE ST PETER PORT Y7 GY1 3RD 001442039817909
Syncona Portfolio Ltd (Filed by) CIK: 0001725042 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Y7 | Fiscal Year End: 0331
Type: SC 13D

Mailing Address STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD, STEVENAGE HERTFORDSHIRE X0 SG1 2FX
Business Address STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD, STEVENAGE HERTFORDSHIRE X0 SG1 2FX 44 (0)1438 906870
Freeline Therapeutics Holdings plc (Subject) CIK: 0001810031 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91620 | Film No.: 22771409
SIC: 2836 Biological Products, (No Diagnostic Substances)